ARCA Biopharma Expects Data Readout From Mid-Stage COVID-19 Trial In Q1 2022
ARCA biopharma Inc (NASDAQ: ABIO)
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged
The Data and Safety Monitoring Committee (DSMC) has completed a pre-specified interim analysis for ARCA biopharma Inc's (NASDAQ: ABIO) ASPEN-COVID-19 Phase 2b trial evaluating rNAPc2, a small recombinant protein for COVID-19.
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
ARCA Biopharma Announces Enrollment Of First International Patient In Phase 2b Clinical Trial Evaluating rNAPc2 As Potential Treatment For COVID-19
ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the first
ARCA biopharma Q2 EPS $(0.34) Up From $(0.73) YoY
ARCA biopharma (NASDAQ:ABIO) reported quarterly losses of $(0.34) per share. This is a 53.42 percent increase over losses of $(0.73) per share from the same period last year.
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 19)
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Monday
Monday morning, 285 companies reached new 52-week lows.